结直肠癌组织miR-485-5p，miR-1207-3p和miR-590-3p水平表达与临床病理特征及生存的相关性研究

目的　研究 miR-485-5p，miR-1207-3p和 miR-590-3p在结直肠癌演进过程中的表达变化。方法　选取 2019年 1月～ 2020年 1月承德市中心医院病理科归档资料齐全完整的 84例结直肠癌组织石蜡标本和距离癌组织边缘 5cm的癌旁组织石蜡标本。采用免疫组织化学法及荧光定量 PCR法检测以直肠组织制作的标本 miR-485-5p，miR-1207-3p和 miR-590-3p，分析 miR-485-5p，miR-1207-3p和 miR-590-3p在结直肠癌组织演进过程中的表达变化。结果　癌组织 miR-485-5p(3.25±0.32 fmol/L)，miR-1207-3p(1.45±0.14 fmol/L)和 miR-590-3p(2.63±0.26 fmol/L)表达均低于癌旁组织 (7.65±0.76 fmol/L，5.81±0.58 fmol/L，8.95±0.89 fmol/L)，差异有统计学意义（ t=48.900，66.970, 62.470，均 P＜ 0.05)。Ⅲ～Ⅳ期、中、低分化、有淋巴结转移、有肝转移患者 miR-485-5p，miR-1207-3p和 miR-590-3p表达分别低于Ⅰ～Ⅱ期、高分化、无淋巴结转移、无肝转移患者，差异有统计学意义（ t/F=21.338～ 52.835, 均 P＜ 0.05）。死亡组患者 miR-485-5p（1.52±0.15 fmol/L），miR-1207-3p（0.50±0.05 fmol/L）和 miR-590-3p（1.15±0.11 fmol/L）均低于存活组（4.98±0.49 fmol/L，2.40±0.24 fmol/L，4.11±0.41 fmol/L），差异具有统计学意义（t=27.820，31.370, 28.520，均 P＜ 0.05）。 ROC曲线分析显示，三项联合曲线下面积、敏感度和特异度分别为 0.823，86.30%和 87.32%；miR-485-5p分别为 0.699，85.78%和 86.41%；miR-1207-3p分别为 0.768，85.59%和 71.14%；miR-590-3p分别为 0.719，83.62%和 87.62%，三项联合诊断价值大于单独检测。 miR-485-5p，miR-1207-3p和 miR-590-3p之间相关性分析显示， miR-485-5p与 miR-12073p呈正相关（ r=0.457，P=0.005）；miR-485-5p与 miR-590-3p呈正相关（ r=0.314，P=0.003）；miR-1207-3p与 miR590-3p呈正相关（ r=0.332，P=0.002）。结论　血清 miR-485-5p，miR-1207-3p和 miR-590-3p水平联合检测对诊断结直肠癌、判断恶化程度有一定临床价值，且可能作为结直肠癌患者潜在的预后标志物。

Correlation of miR-485-5p,miR-1207-3p,miR-590-3p Level Expression and Clinicopathologic Characteristics and Survival in Colorectal Cancer Tissue

Objective　To investigate the expression changes of miR-485-5p, miR-1207-3p and miR-590-3p during the progression of colorectal cancer. Methods　The archive information which was complete full of 84 cases of colorectal cancer tissue paraffin specimens and 5cm of cancerous tissue edge tissue adjacent to carcinoma specimens of paraffin was selected in Department of Pathology, Central Hospital of Chengde City from January 2019 to January 2020. Used the immunohistochemical method and fluorescence quantitative PCR method to detect miR-485-5p, miR-1207-3p, miR-590-3p, analysis of miR-485-5p, miR-1207-3p and miR-590-3p in the expression changes in the process of evolution of colorectal cancer in the organization. Results　The expressions of miR-485-5p (3.25±0.32 fmol/L), miR-1207-3p (1.45±0.14 fmol/L) and miR-590-3p (2.63±0.26 fmol/L) in cancer tissues were all lower than in the tissues adjacent to the cancerous tissue(7.65±0.76 fmol/L，5.81±0.58 fmol/ L，8.95±0.89 fmol/L),the differences were statistically significant（t=48.900，66.970, 62.470，all P ＜ 0.05).The expressions of miR-485-5p, miR-1207-3p and miR-590-3p in patients with stage Ⅲ～Ⅳ , moderately and poorly differentiated, lymph node metastasis and liver metastasis were lower than those of stage Ⅰ～Ⅱ , well differentiated, no lymph node metastasis and the patients without liver metastasis, the differences were statistically significant （t/F=21.338 ～ 52.835, all P ＜ 0.05）. The miR- 485-5p（1.52±0.15 fmol/L）,miR-1207-3p（0.50±0.05 fmol/L）and miR-590-3p（1.15±0.11 fmol/L） of the death group were lower than those of the survival group（4.98±0.49 fmol/L，2.40±0.24 fmol/L，4.11±0.41 fmol/L）, and the differences were statistically significant （t=27.820, 31.370, 28.520, all P ＜ 0.05）.ROC curve analysis showed that the area under the three joint curves, sensitivity and specificity were 0.823, 86.30% and 87.32% respectively. MiR-485-5p was 0.699, 85.78% and 86.41% respectively.MiR-1207-3p was 0.768, 85.59% and 71.14% respectively.MiR-590-3p were 0.719, 83.62% and 87.62% respectively.Three associations had high predictive value for colorectal cancer. Correlation analysis between miR-485-5p, miR- 1207-3p and miR-590-3p revealed a positive correlation between miR-485-5p and miR-1207-3p (r=0.457, P=0.005). A positive correlation was observed between miR-485-5p and miR-590-3 (r=0.314, P=0.003),and a positive correlation was observed between miR-1207-3p and miR-590-3p (r=0.332, P=0.002). Conclusion　The combined detection of serum miR-485-5p, miR- 1207-3p and miR-590-3p levels has a certain clinical value in the diagnosis of colorectal cancer and the degree of deterioration, and may be used as a potential prognostic marker for patients with colorectal cancer.